Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.UMRX · Entity 3793 | Director | July 01, 2020 | July 06, 2020 |
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | Director | June 28, 2022 | June 30, 2022 |
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director | June 26, 2026 | July 02, 2026 |
| Larimar Therapeutics, Inc.ZFGN · Entity 5634 | Director · 10% owner | January 03, 2018 | January 05, 2018 |
| Sionna Therapeutics, Inc.SION · Entity 5996 | Director | June 17, 2026 | June 18, 2026 |
| Tectonic Therapeutic, Inc.AVRO · Entity 5328 | Director | June 06, 2023 | June 08, 2023 |
| Viridian Therapeutics, Inc.\DEMGEN · Entity 4316 | Director | June 27, 2018 | June 28, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date July 01, 2020 · Filed July 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.47 · Expires 2030-07-01 | Direct | 61,338 |
Reported balance
After 2020-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-01 · Grant · Acquired 61,338 · Balance 61,338 F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2: This option is fully vested at time of grant. F3: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Advisors, LLC and as such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of this pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
F2: This option is fully vested at time of grant.
F3: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Advisors, LLC and as such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of this pecuniary interest therein, if any.
Dianthus Therapeutics, Inc. /DE/
Report date June 28, 2022 · Filed June 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2032-06-27 | Direct | 20,000 |
Reported balance
After 2022-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-28 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders. F2: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders.
F2: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Kymera Therapeutics, Inc.
Report date June 26, 2026 · Filed July 02, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,446,375 |
Reported balance
After 2026-06-29 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-29 · Sale · Disposed 5,549 · Balance 2,446,375 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10). F4: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,431,577 |
Reported balance
After 2026-06-29 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2026-06-29 · Sale · Disposed 14,798 · Balance 2,431,577 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive. F4: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,412,158 |
Reported balance
After 2026-06-29 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2026-06-29 · Sale · Disposed 19,419 · Balance 2,412,158 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive. F4: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,401,310 |
Reported balance
After 2026-06-29 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2026-06-29 · Sale · Disposed 10,848 · Balance 2,401,310 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive. F4: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,393,342 |
Reported balance
After 2026-06-29 transaction · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · 2026-06-29 · Sale · Disposed 7,968 · Balance 2,393,342 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive. F4: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,385,619 |
Reported balance
After 2026-06-29 transaction · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · 2026-06-29 · Sale · Disposed 7,723 · Balance 2,385,619 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive. F4: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,384,685 |
Reported balance
After 2026-06-29 transaction · row 7
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 7 · 2026-06-29 · Sale · Disposed 934 · Balance 2,384,685 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive. F4: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 471,497 |
Reported balance
After 2026-06-29 transaction · row 8
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 8 · 2026-06-29 · Sale · Disposed 770 · Balance 471,497 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10). F11: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 469,364 |
Reported balance
After 2026-06-29 transaction · row 9
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 9 · 2026-06-29 · Sale · Disposed 2,133 · Balance 469,364 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive. F11: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 466,666 |
Reported balance
After 2026-06-29 transaction · row 10
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 10 · 2026-06-29 · Sale · Disposed 2,698 · Balance 466,666 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive. F11: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 465,168 |
Reported balance
After 2026-06-29 transaction · row 11
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 11 · 2026-06-29 · Sale · Disposed 1,498 · Balance 465,168 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive. F11: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 464,064 |
Reported balance
After 2026-06-29 transaction · row 12
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 12 · 2026-06-29 · Sale · Disposed 1,104 · Balance 464,064 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive. F11: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 462,986 |
Reported balance
After 2026-06-29 transaction · row 13
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 13 · 2026-06-29 · Sale · Disposed 1,078 · Balance 462,986 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive. F11: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 462,856 |
Reported balance
After 2026-06-29 transaction · row 14
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 14 · 2026-06-29 · Sale · Disposed 130 · Balance 462,856 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive. F11: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
F2: The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10).
F4: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive.
F11: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
Larimar Therapeutics, Inc.
Report date January 03, 2018 · Filed January 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.18 · Expires 2028-01-03 | Direct | 8,509 |
Reported balance
After 2018-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-03 · Grant · Acquired 8,509 · Balance 8,509 F1: The stock option was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Non-Qualified Stock Option Agreement and shall vest over a period of one year starting January 1, 2018 on a quarterly basis in arrears. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Non-Qualified Stock Option Agreement and shall vest over a period of one year starting January 1, 2018 on a quarterly basis in arrears.
Sionna Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.73 · Expires 2036-06-16 | Direct | 17,340 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 17,340 · Balance 17,340 F1: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. F2: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
F2: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.
Tectonic Therapeutic, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2033-06-05 | Direct | 17,643 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 17,643 · Balance 17,643 F1: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. F2: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.
F2: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Viridian Therapeutics, Inc.\DE
Report date June 27, 2018 · Filed June 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2028-06-26 | Direct | 12,000 |
Reported balance
After 2018-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-27 · Grant · Acquired 12,000 · Balance 12,000 F1: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. F2: This option was granted to Bruce Booth, Ph.D., a director of the Issuer. The proceeds of any sale of shares of common stock issued to Dr. Booth upon exercise of this option will be transferred to Atlas Venture Advisors, Inc. and therefore Dr. Booth disclaims beneficial ownership of such shares, which belongs to Atlas Venture Advisors, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date.
F2: This option was granted to Bruce Booth, Ph.D., a director of the Issuer. The proceeds of any sale of shares of common stock issued to Dr. Booth upon exercise of this option will be transferred to Atlas Venture Advisors, Inc. and therefore Dr. Booth disclaims beneficial ownership of such shares, which belongs to Atlas Venture Advisors, Inc.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vigil Neuroscience, Inc.
Report date August 05, 2025 · Filed August 05, 2025
Section 16 reporting ended · disclosed 2025-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-08-05 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F2: Represents Restricted Stock Units ("RSUs"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU. F3: The Reporting Person is a member of Atlas Venture Associates XII, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon settlement of this award to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Atlas Venture Fund XII, L.P. | 0 |
Reported balance
After 2025-08-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-08-05 · Disposition to issuer · Disposed 4,808,896 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F4: These shares are held directly by Atlas Venture Fund XII, L.P. ("Atlas Venture Fund XII"). The general partner of Atlas Venture Fund XII is Atlas Venture Associates XII, L.P. ("AVA XII LP"). Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP. The Reporting Person is a member of AVA XII LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund XII, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Atlas Venture Opportunity Fund I, L.P. | 0 |
Reported balance
After 2025-08-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-08-05 · Disposition to issuer · Disposed 1,027,978 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F5: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-08-05 · Disposition to issuer · Disposed 7,577 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F5: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. F3: The Reporting Person is a member of Atlas Venture Associates XII, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon settlement of this award to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-08-05 · Disposition to issuer · Disposed 12,155 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F5: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. F3: The Reporting Person is a member of Atlas Venture Associates XII, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon settlement of this award to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-08-05 · Disposition to issuer · Disposed 9,713 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F5: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. F3: The Reporting Person is a member of Atlas Venture Associates XII, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon settlement of this award to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-08-05 · Disposition to issuer · Disposed 13,928 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F5: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. F3: The Reporting Person is a member of Atlas Venture Associates XII, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon settlement of this award to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.39 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-08-05 · Disposition to issuer · Disposed 34,612 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F5: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. F3: The Reporting Person is a member of Atlas Venture Associates XII, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon settlement of this award to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.38 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-08-05 · Disposition to issuer · Disposed 18,068 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F5: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. F3: The Reporting Person is a member of Atlas Venture Associates XII, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon settlement of this award to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-08-05 · Disposition to issuer · Disposed 48,393 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F5: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. F3: The Reporting Person is a member of Atlas Venture Associates XII, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon settlement of this award to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").
F2: Represents Restricted Stock Units ("RSUs"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU.
F3: The Reporting Person is a member of Atlas Venture Associates XII, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon settlement of this award to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
F4: These shares are held directly by Atlas Venture Fund XII, L.P. ("Atlas Venture Fund XII"). The general partner of Atlas Venture Fund XII is Atlas Venture Associates XII, L.P. ("AVA XII LP"). Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP. The Reporting Person is a member of AVA XII LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund XII, except to the extent of his pecuniary interest therein, if any.
F5: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any.
F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 01:55 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 14,513 | $100.42 | $1,457,395.46 |
DisclosureSEC source: 0001451612-26-000015 · form4-06262026_010604.xml · nonDerivative · entry 4 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 599,076 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.95 to $100.9487 inclusive. F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 01:55 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 103,688 | $100.42 | $10,412,348.96 |
DisclosureSEC source: 0001451612-26-000015 · form4-06262026_010604.xml · nonDerivative · entry 3 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,357,833 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.95 to $100.9487 inclusive. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 6,068 | $0.00 Strike: $99.87 | $0.00 |
DisclosureSEC source: 0001193125-26-283141 · ownership.xml · derivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,068 Underlying: Common Stock · 6,068 shares Expires 2036-06-23 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2026 Filed Jun 26, 2026 01:55 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 173 | $99.98 | $17,296.54 |
DisclosureSEC source: 0001451612-26-000015 · form4-06262026_010604.xml · nonDerivative · entry 2 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 613,589 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.95 to $100.1037 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5) through (18). F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2026 Filed Jun 26, 2026 01:55 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,235 | $99.98 | $123,475.30 |
DisclosureSEC source: 0001451612-26-000015 · form4-06262026_010604.xml · nonDerivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,461,521 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.95 to $100.1037 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5) through (18). F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,253 | $102.48 | $128,407.44 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 30 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 617,663 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.01 to $103.00 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 918 | $101.61 | $93,277.98 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 29 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 618,916 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.00 to $101.98 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,879 | $100.17 | $789,239.43 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 28 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 619,834 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.8925 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,319 | $99.57 | $728,752.83 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 27 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 627,713 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.00 to $99.9942 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,603 | $98.58 | $355,183.74 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 26 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 635,032 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.00 to $98.9997 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,247 | $97.68 | $219,486.96 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 25 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 638,635 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.0018 to $97.99 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,919 | $96.24 | $280,924.56 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 24 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 640,882 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.00 to $96.959 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,648 | $95.12 | $156,757.76 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 23 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 643,801 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.99 to $95.76 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 286 | $94.48 | $27,021.28 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 22 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 645,449 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.93 to $94.91 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,179 | $92.14 | $200,773.06 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 21 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 645,735 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.11 to $92.50 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,990 | $102.48 | $921,295.20 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 20 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,490,653 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.01 to $103.00 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,597 | $101.61 | $670,321.17 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 19 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,499,643 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.00 to $101.98 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 56,348 | $100.17 | $5,644,379.16 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 18 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,506,240 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.8925 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 52,442 | $99.57 | $5,221,649.94 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 17 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,562,588 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.00 to $99.9942 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 25,976 | $98.58 | $2,560,714.08 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 16 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,615,030 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.00 to $98.9997 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 16,084 | $97.68 | $1,571,085.12 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 15 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,641,006 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.0018 to $97.99 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 20,903 | $96.24 | $2,011,704.72 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 14 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,657,090 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.00 to $96.959 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 11,783 | $95.12 | $1,120,798.96 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 13 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,677,993 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.99 to $95.76 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,035 | $94.48 | $192,266.80 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 12 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,689,776 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.93 to $94.91 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 14,921 | $92.14 | $1,374,820.94 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 11 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,691,811 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.11 to $92.50 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:02 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,341 | $104.38 | $139,973.58 |
DisclosureSEC source: 0001451612-26-000012 · form4-06232026_010614.xml · nonDerivative · entry 4 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 613,762 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.11 to $104.8748 inclusive. F5 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:02 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,560 | $103.42 | $264,755.20 |
DisclosureSEC source: 0001451612-26-000012 · form4-06232026_010614.xml · nonDerivative · entry 3 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 615,103 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.0194 to $103.945 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4). F5 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:02 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 9,584 | $104.38 | $1,000,377.92 |
DisclosureSEC source: 0001451612-26-000012 · form4-06232026_010614.xml · nonDerivative · entry 2 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,462,756 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.11 to $104.8748 inclusive. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 01:02 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 18,313 | $103.42 | $1,893,930.46 |
DisclosureSEC source: 0001451612-26-000012 · form4-06232026_010614.xml · nonDerivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,472,340 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.0194 to $103.945 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4). F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 793 | $92.16 | $73,082.88 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 10 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 647,914 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.1191 to $92.2833 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,526 | $91.85 | $415,713.10 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 9 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 648,707 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.10 to $92.085 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,809 | $90.48 | $797,038.32 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 8 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 653,233 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.04 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,672 | $92.16 | $522,731.52 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 7 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,706,732 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.1191 to $92.2833 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 32,359 | $91.85 | $2,972,174.15 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 6 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,712,404 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.10 to $92.085 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 62,897 | $90.48 | $5,690,920.56 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 5 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,744,763 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.04 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 21:29 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,340 | $0.00 Strike: $36.73 | $0.00 |
DisclosureSEC source: 0001451612-26-000008 · edgardoc.xml · derivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,340 Underlying: Common Stock · 17,340 shares Expires 2036-06-16 F1 · security: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. F2 · derivative.exercise_date: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 17, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,741 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · derivative · entry 31 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,127 Underlying: Common Stock · 11,741 shares Expires 2030-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F20 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| June 17, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 12,902 | $90.38 | $1,166,082.76 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 4 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 662,042 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.03 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 17, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 92,169 | $90.38 | $8,330,234.22 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 3 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,807,660 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.03 inclusive. F5 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 17, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 11,741 | $89.98 | $1,056,455.18 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 2 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.95 to $90.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4) and (7) through (19). Read SEC document |
| June 17, 2026 Filed Jun 23, 2026 01:01 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 11,741 | $20.00 | $234,820.00 |
DisclosureSEC source: 0001451612-26-000010 · form4-06232026_010608.xml · nonDerivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:33 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 259 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001451612-26-000006 · form4-04242026_080445.xml · derivative · entry 7 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,868 Underlying: Common Stock · 259 shares Expires 2030-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:33 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,641 | $0.00 Strike: $14.18 | $0.00 |
DisclosureSEC source: 0001451612-26-000006 · form4-04242026_080445.xml · derivative · entry 6 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,641 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:33 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 12 | $90.08 | $1,080.96 |
DisclosureSEC source: 0001451612-26-000006 · form4-04242026_080445.xml · nonDerivative · entry 5 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 674,944 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. F5 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:33 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 88 | $90.08 | $7,927.04 |
DisclosureSEC source: 0001451612-26-000006 · form4-04242026_080445.xml · nonDerivative · entry 4 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 3,899,829 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. F4 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:33 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,900 | $89.96 | $530,764.00 |
DisclosureSEC source: 0001451612-26-000006 · form4-04242026_080445.xml · nonDerivative · entry 3 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.95 to $90.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in this footnote. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:33 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 259 | $20.00 | $5,180.00 |
DisclosureSEC source: 0001451612-26-000006 · form4-04242026_080445.xml · nonDerivative · entry 2 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:33 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 5,641 | $14.18 | $79,989.38 |
DisclosureSEC source: 0001451612-26-000006 · form4-04242026_080445.xml · nonDerivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 22:16 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,200 | $0.00 Strike: $14.18 | $0.00 |
DisclosureSEC source: 0001451612-26-000004 · form4-04162026_100449.xml · derivative · entry 8 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,641 Underlying: Common Stock · 2,200 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 22:16 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 385 | $90.10 | $34,688.50 |
DisclosureSEC source: 0001451612-26-000004 · form4-04162026_100449.xml · nonDerivative · entry 6 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 674,956 F4 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $90.145 inclusive. F7 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.